AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib) is ...

ASH: AstraZeneca proposes fixed-duration Calquence combos in chronic lymphocytic leukemia By Angus Liu Dec 8, 2024 11:00am AstraZeneca ASH 2024 Calquence chronic lymphocytic leukemia ...

FDA fully approves AstraZeneca's Calquence combo therapy, reducing MCL progression/death risk by 27% in Phase 3 ECHO trial. Median progression-free survival extended to 66.4 months with Calquence ...

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib), plus bendamustine and rituximab, to treat adults with previously ...

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the treatment of ...

AstraZeneca’s Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for the treatment of adult patients with previously untreated ...

AstraZeneca’s Calquence approved by EC for first-line chronic lymphocytic leukaemia use. An estimated 27,000 cases of the disease were diagnosed in the UK, France, Germany, Spain and Italy in 2024.

AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).

Results from the AMPLIFY trial showed 77% of patients treated with Calquence plus venetoclax and 83% of patients treated with Calquence plus venetoclax and obinutuzumab were progression free at three ...